Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
Holly JanesLeigh H FisherJia Jin KeeLalitha ParameswaranPaul A GoepfertAnn R FalseyJames LudwigCraig A MagaretPeter B GilbertJames G KublinNadine G RouphaelMagdalena E SobieszczykHana M El SahlyLindsey R BadenBeatriz GrinsztejnStephen R WalshGlenda E GrayKaren L KotloffCynthia L GayAlexander L GreningerMilagritos D TapiaE Adrianne HammershaimbFrances H PriddyJustin A GreenFrank StruyfLisa DunkleKathleen M NeuzilLawrence CoreyYunda HuangPublished in: The Journal of infectious diseases (2024)
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in VL at COVID-19 diagnosis in 4 phase 3 randomized, placebo-controlled vaccine trials, July 2020 to July 2021, VL reductions were 2.78 log10 copies/mL (95% confidence interval [CI], 1.38-4.18; n = 60 placebo, 11 vaccine) and 2.12 log10 copies/mL (95% CI, 1.44-2.80; n = 594 placebo, 36 vaccine) for NVX-CoV2373 and mRNA-1273, respectively. Associations were not significant for AZD1222 (0.59 log10 copies/mL; 95% CI, -.19 to 1.36; n = 90 placebo, 78 vaccine) or Ad26.COV2.S (0.23 log10 copies/mL; 95% CI, -.01 to .47; n = 916 placebo, 424 vaccine). Thus, vaccines potentially decreased transmission when ancestral SARS-CoV-2 predominated. Clinical Trials Registration. NCT04470427, NCT04505722, NCT04516746, NCT04611802.